ZTlido (lidocaine) Patch Won FDA Approval For The Treatment Of Postherpetic Neuralgia

ZTlido (lidocaine) Patch Won FDA Approval For The Treatment Of Postherpetic Neuralgia

FDA Approves Scilex Pharmaceuticals’s ZTlido (lidocaine) For The Treatment Of Postherpetic Neuralgia

Company: Scilex Pharmaceuticals, Inc.

Brand Name: ZTlido

Generic Name: lidocaine

Dosage Form: Patch

Previous Name: Ztilido

Treatment for: Postherpetic Neuralgia

 

 

General information about ZTlido

ZTlido (lidocaine topical system 1.8%) is a transdermal anesthetic formulation for the treatment of pain associated with post-herpetic neuralgia ("PHN"), a severe neuropathic pain condition.

ZTlido is a single-layered anhydrous patch featuring proprietary technology that offers advantages over the multi-layered hydrogel patches. Containing only 36 mg of lidocaine per patch, compared to the 700 mg found in the multi-layered hydrogel system, ZTlido 1.8% patches use a specialized construction that makes them thinner, more adhesive and more flexible, with a rate-controlling membrane designed for more effective lidocaine delivery.

 

Top